Tamoxifen Use in Patients with Ductal Carcinoma In Situ and T1a/b N0 Invasive Carcinoma

Nakhlis, Faina; Lazarus, Laura; Hou, Nanjiang; Acharya, Simbi; Khan, Seema A.; Staradub, Valerie L.; Rademaker, Alfred; Morrow, Monica

doi:10.1016/j.jamcollsurg.2005.06.195

Cited by 23 publications

(18 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In multivariable analysis, Latina Spanish-speaking women were less likely than white women to discuss adjuvant HT with their physicians, in contrast to research by Nakhlis et al, 18 which found no differences according to race/ ethnicity in the proportion of women who were offered tamoxifen for treatment of in situ or early stage breast cancer by their physicians. Prior research indicates that Latina women in particular perceive the physician-patient relationship as important and may rely heavily on physicians to make treatment decisions.…”

Section: Discussioncontrasting

confidence: 85%

“…However, wide practice variation in recommendations for use and uptake of these therapies for DCIS suggests that communication with physicians can exert a strong influence on whether or not patients use these medications. 1,13,18,19 This study identified several patient, tumor, treatment, and physician-patient communication-related factors associated with the discussion, use, and discontinuation of adjuvant HT in a demographically and ethnically diverse sample of women.…”

Section: Discussionmentioning

confidence: 99%

“…1,11,[14][15][16][17] As a result, there is a lack of consistency in both the recommendations for and uptake of tamoxifen use in the setting of DCIS. 1,18,19 The NSABP B35 trial is currently underway to compare the effectiveness of anastrazole (an aromatase inhibitor) to that of tamoxifen in postmenopausal women with hormone receptor-positive DCIS. 11,20 Previous research into factors associated with use of adjuvant HT has focused on women with invasive breast cancer, where its use has been more consistently recommended as standard of care.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Adjuvant Hormonal Therapy Use Among Women with Ductal Carcinoma In Situ

Livaudais

Hwang

Karliner

et al. 2012

Journal of Women's Health

View full text Add to dashboard Cite

Objective: In the absence of consistent guidelines for the use of adjuvant hormonal therapy (HT) in treating ductal carcinoma in situ (DCIS), our purpose was to explore a variety of factors associated with discussion, use, and discontinuation of this therapy for DCIS, including patient, tumor, and treatment-related characteristics and physician-patient communication factors. Methods: We identified women from eight California Cancer Registry regions diagnosed with DCIS from 2002 through 2005, aged ‡ 18 years, of Latina or non-Latina white race/ethnicity. A total of 744 women were interviewed an average of 24 months postdiagnosis about whether they had (1) discussed with a physician, (2) used, and (3) discontinued adjuvant HT. Results: Although 83% of women discussed adjuvant HT with a physician, 47% used adjuvant HT, and 23% of users reported discontinuation by a median of 11 months. In multivariable adjusted analyses, Latina Spanish speakers were less likely than white women to discuss therapy (odds ratio [OR] 0.36, 95% confidence interval [CI] 0.18-0.69) and more likely to discontinue therapy (OR 2.67, 95% CI 1.05-6.81). Seeing an oncologist for follow-up care was associated with discussion (OR 5.10, 95% CI 3.14-8.28) and use of therapy (OR 4.20, 95% CI 2.05-8.61). Similarly, physician recommendation that treatment was necessary vs. optional was positively associated with use (OR 11.2,) and inversely associated with discontinuation (OR 0.38,. Conclusions: Physician recommendation is an important factor associated with use and discontinuation of adjuvant HT for DCIS. Differences in discussion and discontinuation of therapy according to patient characteristics, particularly ethnicity/language, suggest challenges to physician-patient communication about adjuvant HT across a language barrier.

show abstract

Section: Discussioncontrasting

confidence: 85%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Adjuvant Hormonal Therapy Use Among Women with Ductal Carcinoma In Situ

Livaudais

Hwang

Karliner

et al. 2012

Journal of Women's Health

View full text Add to dashboard Cite

show abstract

“…Instead, we observed that women who had BCS with radiation were most likely to initiate endocrine therapy. Nakhlis et al reported that a higher proportion of women who had BCS used tamoxifen compared with women who had a mastectomy after DCIS (80% vs. 46%; p = .002) at the Lynn Sage Breast Center in Chicago during 1998–2001; radiation therapy was not evaluated [30]. The association between primary DCIS treatment and endocrine therapy use reported by Livaudais et al was not statistically significant, but in the same direction as our own: compared with mastectomy, women who reported BCS with radiation were more likely to use endocrine therapy (odds ratio [OR] 1.34; 95% CI 0.77–2.31 across eight California Cancer Registry regions during 2002–2005) [29].…”

Section: Discussionmentioning

confidence: 99%

“…One previous report using data from the North Carolina Central Cancer Registry observed no association between ER status and endocrine therapy initiation in 1998–1999; however, ER testing was not performed for 85% of DCIS diagnoses [31]. ER status was not associated with tamoxifen use in an analysis of women treated for DCIS at the Lynn Sage Breast Center in Chicago during 1998–2001 [30]. …”

Section: Discussionmentioning

confidence: 99%

Tamoxifen Initiation After Ductal Carcinoma In Situ

et al. 2016

View full text Add to dashboard Cite

show abstract

Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ

Hird

Chang

Cimmino

et al. 2006

Cancer

View full text Add to dashboard Cite

The iterated unscented Kalman filter (IUKF) is a promising nonlinear tracking algorithm. However, we find that the IUKF has poor performance in tracking accuracy and will diverge easily when the variance of observation noise is large, because the iterated state prediction is nonorthogonal to the current observation after the first iteration. This will increase the proportion of current observation in state estimate and lead to the tendency for the final iteration result to be closer to the observation compared with the optimal solution, which is a phenomenon termed the nonorthogonal problem here. We solve this problem by augmenting the state vector with the process and observation noise vectors and slightly reconstructing the IUKF formula. Simulation results show that the proposed algorithm has better tracking performance than IUKF. © 2013 Institute of Electrical Engineers of Japan. Published by John Wiley & Sons, Inc.

show abstract

Tamoxifen Use in Patients with Ductal Carcinoma In Situ and T1a/b N0 Invasive Carcinoma

Cited by 23 publications

References 32 publications

Adjuvant Hormonal Therapy Use Among Women with Ductal Carcinoma In Situ

Adjuvant Hormonal Therapy Use Among Women with Ductal Carcinoma In Situ

Tamoxifen Initiation After Ductal Carcinoma In Situ

Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ

Contact Info

Product

Resources

About